Fan S T, Lo C M, Man K
Department of Surgery, Queen Mary Hospital, Hong Kong.
Zhonghua Yi Xue Za Zhi. 1996 Apr;76(4):267-70.
To explore the experience of liver transplantation in patients with terminal liver failure.
From October 1991 to July 1995, 17 adults and 6 children underwent orthotopic liver transplantation. Preoperative diagnosis showed biliary atresia (n = 5), Alagille syndrome (n = 1), primary biliary cirrhosis (n = 2), cryptogenic cirrhosis (n = 2), alcoholic cirrhosis (n = 4), Wilson's disease (n = 1), fulminant hepatic failure (n = 3), polycystic liver (n = 2), secondary biliary cirrhosis (n = 1), hepatitis B cirrhosis (n = 1), and autoimmune hepatitis associated with a small hepatocellular carcinoma (n = 1). One paediatric patient suffered from hepatitis of unknown aetiology which progressed to liver failure after liver transplantation. She received retransplantation using a living graft from her mother. The liver grafts were obtained from 17 brainstem dead donors and 7 living donors.
The overall patient survival rate was 92% and graft survival rate was 88%. There were only 2 deaths, one was due to primary graft nonfunction and the other was due to persistent graft rejection not responding to pulse steroid and OKT3. The other patients are alive and well.
Liver transplantation is a feasible and viable treatment for patients with terminal liver failure in Hong Kong. The only limitation is lack of brainstem dead donor. Promotion of concept of brainstem death and organ donation in the society is the key to wide use of liver transplantation for patients with terminal liver failure in Asia.
探讨终末期肝衰竭患者肝移植的经验。
1991年10月至1995年7月,17例成人和6例儿童接受了原位肝移植。术前诊断显示为胆道闭锁(n = 5)、阿拉吉列综合征(n = 1)、原发性胆汁性肝硬化(n = 2)、隐源性肝硬化(n = 2)、酒精性肝硬化(n = 4)、威尔逊病(n = 1)、暴发性肝衰竭(n = 3)、多囊肝(n = 2)、继发性胆汁性肝硬化(n = 1)、乙型肝炎肝硬化(n = 1)以及与小肝细胞癌相关的自身免疫性肝炎(n = 1)。1例儿科患者患有病因不明的肝炎,肝移植后进展为肝衰竭。她接受了来自其母亲的活体肝移植进行再次移植。肝移植物来自17例脑死亡供体和7例活体供体。
总体患者生存率为92%,移植物生存率为88%。仅2例死亡,1例死于原发性移植物无功能,另1例死于对脉冲类固醇和OKT3无反应的持续性移植物排斥反应。其他患者均存活且情况良好。
肝移植对于香港终末期肝衰竭患者是一种可行的治疗方法。唯一的限制是缺乏脑死亡供体。在社会上推广脑死亡和器官捐献的观念是亚洲地区广泛应用肝移植治疗终末期肝衰竭患者的关键。